HIV Malignancy Specimens for Research at No Charge
It’s National Cancer Prevention and Early Detection Month!(https://www.whitehouse.gov/briefing-room/presidential-actions/2024/03/29/a-proclamation-on-cancer-control-month-2024/). Human papillomavirus (HPV) is the most the common sexually transmitted infection (STI) in the United States (per CDC’s STD Facts on HPV), and is …
Join the world’s EBV and KSHV experts at the upcoming 3rd Joint International Symposium on EBV & KSHV & Related Agents & Diseases: June 29-July 3, 2024 Boston, USA. The …
The NIH Office of AIDS Research (OAR) has issued a Request for Information (RFI) to inform development of the FY 2026‒2030 NIH Strategic Plan for HIV and HIV-Related Research. Feedback …
February is National Cancer Prevention Month and World Cancer Day is on February 4th. The ACSR is committed to advancing the science of cancer prevention. Screening, vaccines and making healthy …
The ACSR is delighted to extend an upcoming learning opportunity courtesy of the January Journal of Visualized Experiments (JoVE) webinar “Enhancing Tumor Content: Macrodissection Method,” to learn a relatively quick …
Drs. Elaine Jaffe, Louis Staudt and Robert Yarchoan at The National Institutes of Health recipients of Departmental Awards from the U.S. Department of Health and Human Services (HHS) for their groundbreaking research leading to …
The ACSR extends a warm welcome to Dr. Kim Rathmell, NCI Director. Dr. W. Kimryn Rathmell began her work as 17th director of the National Cancer Institute on December 18th …
We are thrilled to announce ACSR’s highly valued relationship with Proscia®. Read the full release below for more on how enterprise digital pathology thru Proscia Concentriq is helping the ACSR …
The National Cancer Institute’s Division of Cancer Epidemiology and Genetics released a summary of 3 studies that have the potential for informing recommendations for anal cancer screening, the importance of …
Learn more about ComboMATCH: the new clinical trial initiative to evaluate combinations of treatments that block both the drivers of tumor growth and the mechanisms of resistance. The primary goal for ComboMATCH …